Company: PRME
Filing Date: 2025-02-28
Form Type: 10-K
Source: 0001628280-25-008884
Chunk: 254

Company: Prime Medicine, Inc.
Filing Date: 2025-02-28
Form: 10-K
Item: Item 16
Chunk 254
---
500 Deferred revenue — related party7,092 — Operating lease liability3,614 9,276 Total current liabilities37,961 56,423 Deferred revenue, net of current — related party63,218 — Operating lease liability, net of current37,180 4,357 Research and development funding liability6,000 — Total liabilities144,359 60,780 Commitments and contingencies (Note 12)Stockholders’ equityCommon stock, par value of $0.00001 per share; 775,000,000 shares authorized; 131,160,842 and 97,377,121 shares issued and outstanding as of December 31, 2024 and 2023, respectively2 2 Additional paid-in capital840,358 624,414 Accumulated other comprehensive loss1 (15)Accumulated deficit(687,212)(491,330)Total stockholders’ equity153,149 133,071 Total liabilities and stockholders’ equity$297,508 $193,851 

The accompanying notes are an integral part of these consolidated financial statements.

F-3

PRIME MEDICINE, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

Year Ended December 31,(in thousands, except share and per share amounts)20242023Revenue:Collaboration revenue — related party$1,609 $— Collaboration revenue1,374 — Total revenue2,983 — Operating expenses:Research and development (1)155,289 147,905 Settlement payment — related party— 13,500 General and administrative50,161 43,387 Total operating expenses205,450 204,792 Loss from operations(202,467)(204,792)Other income:Interest income3,522 2,811 Accretion (amortization) of investments3,507 5,677 Change in fair value of short-term investment — related party(485)(2,382)Other income, net41 274 Total other income, net6,585 6,380 Net loss before income taxes(195,882)(198,412)Benefit from income taxes— 279 Net loss attributable to common stockholders$(195,882)$(198,133)Net loss per share attributable to common stockholders, basic and diluted$(1.65)